A Multicentre, Open-label, Dose-finding, Phase 2 Study to Investigate the Efficacy, and Safety of Different Doses of LY01021 in Controlled Ovarian Hyperstimulation(COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
Latest Information Update: 27 Nov 2025
At a glance
- Drugs LY 01021 (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- Sponsors Luye Pharma Group
Most Recent Events
- 27 Nov 2025 New trial record